Generic Ibrance Availability
Last updated on Mar 9, 2023.
Ibrance is a brand name of palbociclib, approved by the FDA in the following formulation(s):
IBRANCE (palbociclib - capsule;oral)
-
Manufacturer: PFIZER
Approval date: February 3, 2015
Strength(s): 75MG [RLD], 100MG [RLD], 125MG [RLD]
IBRANCE (palbociclib - tablet;oral)
-
Manufacturer: PFIZER
Approval date: November 1, 2019
Strength(s): 75MG [RLD], 100MG [RLD], 125MG [RLD]
Has a generic version of Ibrance been approved?
No. There is currently no therapeutically equivalent version of Ibrance available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ibrance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 10,723,730
Patent expiration dates:
- February 8, 2034✓✓
- February 8, 2034
-
Patent 11,065,250
Patent expiration dates:
- May 24, 2036✓
- May 24, 2036
-
2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Patent 6,936,612
Issued: August 30, 2005
Inventor(s): Barvian; Mark & Booth; Richard John & Quin, III; John & Repine; Joseph Thomas & Sheehan; Derek J. & Toogood; Peter Laurence & Vanderwel; Scott Norman & Zhou; Hairong
Assignee(s): Warner-Lambert CompanyThe present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4)
Patent expiration dates:
- January 16, 2023✓✓
- January 16, 2023
-
2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Patent 7,208,489
Issued: April 24, 2007
Inventor(s): Barvian; Mark & Booth; Richard John & Quin, III; John & Repine; Joseph Thomas & Sheehan; Derek J. & Toogood; Peter Laurence & Vanderwel; Scott Norman & Zhou; Hairong
Assignee(s): Warner-Lambert CompanyThe present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4)
Patent expiration dates:
- January 16, 2023✓✓✓
- January 16, 2023
-
2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
Patent 7,456,168
Issued: November 25, 2008
Inventor(s): Barvian; Mark & Booth; Richard John & Quin, III; John & Repine; Joseph Thomas & Sheehan; Derek J. & Toogood; Peter Laurence & Vanderwel; Scott Norman & Zhou; Hairong
Assignee(s): Warner-Lambert CompanyThe present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
Patent expiration dates:
- January 16, 2023✓
- January 16, 2023✓
- January 16, 2023✓
- January 16, 2023
-
Patent RE47739
Patent expiration dates:
- March 5, 2027✓✓
- March 5, 2027
More about Ibrance (palbociclib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (70)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: CDK 4/6 inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.